10-K: Adicet Bio Reports Full Year 2023 Results, Outlines 2024 Clinical and Pipeline Milestones

Adicet Bio's 2023 10-K filing details progress in clinical trials for ADI-001 and ADI-270, along with plans for further development in autoimmune diseases and cancer.

Summary

• Adicet Bio, a clinical-stage biotechnology company, is focused on developing allogeneic gamma delta T-cell therapies for autoimmune diseases and cancer.
• The company's lead product candidate, ADI-001, is being developed for autoimmune diseases and relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL).
• A Phase 1 clinical trial for ADI-001 in lupus nephritis is expected to begin in the second quarter of 2024, with preliminary data anticipated in late 2024 or early 2025.
• The company is also advancing ADI-270, a preclinical candidate targeting renal cell carcinoma, with an IND application planned for the second quarter of 2024 and clinical data expected in the first half of 2025.
• Adicet Bio plans to file one new Investigational New Drug (IND) application every 12-18 months.
• The company reported a net loss of $142.7 million for the year ended December 31, 2023, and had cash and cash equivalents of $159.7 million as of the same date.
• Subsequent to year end, the company raised approximately $19.3 million through an ATM program and $91.8 million through an underwritten public offering.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical trials and pipeline development, the company is still in the early stages and faces significant financial and development risks. The increased net loss and need for additional financing are concerning.

Positives

• The company has a proprietary allogeneic gamma delta T-cell platform that allows for rapid and cost-efficient product candidate generation.
• ADI-001 has shown promising early clinical results in MCL patients, with high response rates and favorable durability.
• The company has expanded manufacturing capabilities for ADI-001, which is critical for future clinical trials and potential commercialization.
• The company has a pipeline of additional gamma delta T-cell therapy programs in preclinical development.
• The company has a strategic collaboration with Regeneron, which provides funding and access to technology.

Negatives

• The company has a limited operating history and has incurred net losses since its inception.
• The company is highly dependent on the success of ADI-001, and any setbacks could significantly harm the business.
• The company's product candidates are based on novel technologies, which makes it difficult to predict their success.
• The company relies on third parties for manufacturing, which increases the risk of supply disruptions.
• The company will need substantial additional financing to develop its product candidates and implement its operating plans.

Risks

• The company has a limited operating history and faces significant challenges and expenses as it builds its capabilities.
• The company's business is highly dependent on the success of ADI-001.
• The company's gamma delta T cell candidates represent a novel approach, which creates significant challenges.
• The company's clinical trials may fail to demonstrate the safety and efficacy of its product candidates.
• The company may not be able to file IND applications on the timelines it expects.
• The company may encounter substantial delays in its clinical trials.
• The market opportunities for the company's product candidates may be limited.
• The company is highly dependent on its key personnel.
• The company will need substantial additional financing to develop its product candidates.
• Business disruptions could seriously harm the company's future revenue and financial condition.
• Global conflicts may increase the likelihood of supply interruptions.
• Failure to achieve and maintain effective internal control over financial reporting could harm the company's business.
• If the company's collaboration with Regeneron is terminated, its business would be materially harmed.
• The FDA regulatory approval process is lengthy and time-consuming.
• If the company's efforts to protect its intellectual property are not adequate, it may not be able to compete effectively.
• The company depends on intellectual property licensed from third parties.
• The trading price of the company's common stock is highly volatile.
• Unstable market and economic conditions may have serious adverse consequences on the company's business.

Future Outlook

The company plans to continue advancing clinical development of ADI-001 and ADI-270, and to innovate and invest in its gamma delta T cell platform and pipeline. The company expects to file one new IND application every 12-18 months.

Management Comments

• The company plans to focus on advancing MCL enrollment in the GLEAN trial and has deprioritized enrolling large B-cell lymphoma patients.
• The company expects to provide a clinical update from the Phase 1 study in NHL patients which will include efficacy data, including six-month CR rate, and safety data from additional MCL patients in the second half of 2024.
• Subject to clinical data and regulatory feedback, in the first half of 2025, the company plans to define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL and provide a further clinical update in the second half of 2025.

Industry Context

The document highlights the growing interest in CAR T-cell therapy for autoimmune diseases, and the potential advantages of gamma delta T-cell therapies over traditional alpha beta T-cell therapies. The company is positioning itself as a leader in the development of allogeneic gamma delta T-cell therapies.

Comparison to Industry Standards

• The document compares ADI-001's exposure, measured by Cmax, D28 persistence and AUC, to values reported for approved autologous CD19 CAR T therapies, suggesting a similar or better profile.
• The document notes that ADI-001 has demonstrated deep cytoreductive complete responses that surpass the depth of response demonstrated by autologous CAR T therapy in the same patient.
• The document highlights that ADI-001 has shown to be well tolerated with no significant CRS, ICANS and an inherently lower risk of T-cell malignancies compared to autologous CAR-Ts, which is a key differentiator.
• The document also compares the company's gamma delta T-cell approach to other allogeneic T-cell therapy competitors, such as Sana Biotechnology, CRISPR Therapeutics, Fate Therapeutics, Nkarta, and Century Therapeutics, and to autologous T-cell therapy competitors, such as Novartis, Bristol-Myers Squibb, Autolus Therapeutics, Cartesian Therapeutics, iCell Gene Therapeutics, Cabaletta Bio, Gracell Biotechnologies, and Kyverna Therapeutics.

Related Party Transactions

• The company has a license and collaboration agreement with Regeneron Pharmaceuticals, Inc., which is a related party due to its ownership of the company's common stock.

Stakeholder Impact

• Shareholders face risks due to the company's need for additional financing and the volatility of its stock price.
• Employees are subject to the company's insider trading policy and may be affected by changes in the company's financial condition.
• Patients may benefit from the development of new therapies for autoimmune diseases and cancer.
• The company's suppliers and manufacturers are subject to the company's reliance on third parties and potential supply disruptions.

Next Steps

• Initiate a Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024.
• Expand development of ADI-001 into one to two additional autoimmune indications in the second and third quarters of 2024.
• File an IND application for ADI-270 in RCC in the second quarter of 2024.
• Provide a clinical update from the Phase 1 study in NHL patients in the second half of 2024.
• Define the regulatory path for a potentially pivotal Phase 2 study for ADI-001 in MCL in the first half of 2025.
• Provide a further clinical update for ADI-001 in the second half of 2025.
• Continue to develop product candidates in autoimmune diseases and cancer based on the gamma delta T cell platform.

Key Dates

Keywords

gamma delta T cell therapy, allogeneic, CAR T-cell, autoimmune diseases, cancer, ADI-001, ADI-270, lupus nephritis, non-Hodgkin's lymphoma, renal cell carcinoma, clinical trials, biotechnology